icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Asunaprevir With Peginterferon-Alfa and Ribavirin in Treatment-Naive Patients With Genotype-1 or -4 Chronic Hepatitis C: SVR24 Results From a Randomized Phase 2b Study (AI447-016)
 
 
  Reported by Jules Levin
EASL 2013 Amsterdam April 26
 
Bronowicki J-P,1 Ratziu V,2 Gadano A,3 Thuluvath PJ,4 Bessone F,5 Martorell CT,6 Pol S,7 Terg R,8 Younes Z,9 He B,10 Eley T,10 Cohen D,11 Mendez P,10 Hughes EA10 1Centre Hospitalier Universitaire de Nancy, Université de Lorraine, Vandoeuvre les Nancy, France; 2Groupe Hospitalier Pitié Salpêtrière, Paris, France; 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 4Mercy Medical Center, Baltimore, MD, USA;
5Hospital Provincial del Centenario, University of Rosario School of Medicine, Rosario, Argentina; 6The Research Institute, Springfield, MA, USA; 7Université Paris Descartes, Hôpital Cochin, Paris, France; 8Universidad del Salvador Hospital de Gastroenterología Bonorino Udaondo, Buenos Aires, Argentina; 9Gastro One, Germantown, TN, USA; 10Bristol-Myers Squibb, Princeton, NJ, USA; 11Bristol-Myers Squibb, Wallingford, CT, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif